Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04027348 · ClinicalTrials.gov registry record · Phase 2
Palliative Management of Inoperable Malignant Bowel Obstruction
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT04027348 is a Phase 2 study that was terminated before completion, run by Roswell Park Cancer Institute. The registered enrollment target is 15 participants.
The verdict
NCT04027348, a Phase 2 study, was terminated before completion, sponsored by Roswell Park Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
To identify the role of palliative medical management of inoperable malignant bowel obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple therapy.
Interventions
- DRUG Dexamethasone
- DRUG Metoclopramide
- DRUG Octreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-06-26 |
| Est. Completion | 2021-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04027348
The ClinicalTrials.gov registry entry for NCT04027348 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT04027348 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04027348 about?
NCT04027348 is a clinical study titled "Palliative Management of Inoperable Malignant Bowel Obstruction". To identify the role of palliative medical management of inoperable malignant bowel obstruction (MBO) with Octreotide, Dexamethasone and Metoclopramide given together as triple therapy.
What is the current status of trial NCT04027348?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-06-26. Estimated completion is 2021-09-03.
What interventions are being tested in trial NCT04027348?
The interventions under investigation include: Dexamethasone (DRUG), Metoclopramide (DRUG), Octreotide (DRUG).
Who is sponsoring clinical trial NCT04027348?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.